Tyrosine kinase inhibitors and COVID-19
- PMID: 33081581
- DOI: 10.1177/1078155220967081
Tyrosine kinase inhibitors and COVID-19
Comment on
-
Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors.J Oncol Pharm Pract. 2020 Dec;26(8):2068-2069. doi: 10.1177/1078155220967100. Epub 2020 Oct 21. J Oncol Pharm Pract. 2020. PMID: 33081582 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
